Alaska Permanent Fund’s Vir Biotechnology VIR Stock Holding History

Alaska Permanent Fund’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,300,000	Closed	-$58.6M	–	418
2022 Q2	$58.6M	Hold	2,300,000	–	–	0.84%	19
2022 Q1	$59.2M	Hold	2,300,000	–	–	0.98%	15
2021 Q4	$79M	Sell	2,300,000 -1,272,438	-36%	-$49.8M	1.44%	15
2021 Q3	$155M	Sell	3,572,438 -227,562	-6%	-$9.85M	3.08%	11
2021 Q2	$180M	Hold	3,800,000	–	–	3.28%	11
2021 Q1	$195M	Sell	3,800,000 -1,000,000	-21%	-$53.9M	3.53%	12
2020 Q4	$129M	Hold	4,800,000	–	–	2.33%	17
2020 Q3	$165M	Hold	4,800,000	–	–	2.64%	13
2020 Q2	$197M	Buy	4,800,000 +3,300,000	+220%	+$111M	3.05%	8
2020 Q1	$51.4M	Buy	+1,500,000	New	+$40.3M	0.9%	23

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alaska Permanent Fund's VIR Position: Q3 2022 in Review

Alaska Permanent Fund sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 2,300,000 shares — an estimated $58.6M sold.

Alaska Permanent Fund first reported a position in VIR in Q1 2020 and held it in 10 quarters. The position peaked at $197M in Q2 2020. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

Alaska Permanent Fund reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
Alaska Permanent Fund sold 2,300,000 Vir Biotechnology shares in Q3 2022, an estimated $58.6M.
Alaska Permanent Fund first reported a position in Vir Biotechnology in Q1 2020 and held it in 10 quarters.
Alaska Permanent Fund's Vir Biotechnology position peaked at $197M in Q2 2020.
221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Alaska Permanent Fund's 13F filing for Q3 2022, filed 1 Nov 2022.